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Genetic polymorphism of CYPZEI was investigated among 195 Swedish patients with lung cancer and 206 controls. Three different polymorphic 
sites were found, all in introns, using RFLP and the restriction enzymes DruI, RraI and TuqI. The frequencies of the rare alleles were 0.08-0.18 
and much lower than previously described among Japanese. No significant difference in distribution of the polymorphic alleles between controls 
and lung cancer patients was evident, in contrast to results of a previous Japanese study. However, examination of a polymorphic site in the 
5’-flanking region, within a putative binding motif for the hepatic transcription factor HNF-1, revealed a significantly less frequent distribution 
of the mutated allele (cz) among the lung cancer patients as compared to controls. It is concluded that major interethnic differences exist in the 
genetic polymorphism of CYPZEI and that people carrying the ct allele might be at lower risk for developing lung cancer. 
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1. INTRODUCTION 
Ethanol-inducible cytochrome P450 2El (CYP2El) 
metabolizes everal suspect as well as established carcin- 
ogens [1,2]. More than 75 specific substrates for 
CYP2El have been identified [2], most of them small 
and hydrophobic in nature. Among the substrates are 
several potentially important carcinogens such as ben- 
zene, dimethylnitrosoamine, vinyl chloride and dieth- 
yldithiocarbamate. CYP2El is localised in several dif- 
ferent tissues, among them the brain [3] and the lung [4], 
but the highest expression is in the liver. The hepatic 
distribution of CYP2El is almost entirely in the cen- 
trilobular region [5] and the amount of the isozyme can 
here reach approximately 0.1 mM after induction. The 
regional distribution of CYP2El correlates well to the 
areas where the hepatotoxic chemicals, known to be 
activated by CYP2E1, exert their toxic action [2]. 
of the important role of CYP2El in the metabolic acti- 
vation of carcinogens, it might be speculated that differ- 
ent allelic CYPZEZ forms would cause formation of 
altered variants of CYP2E1, alternatively cause differ- 
ent levels of enzyme expression. This might be impor- 
tant for the rate of metabolic activation and, hence, for 
the individual susceptibility to carcinogen exposure. In 
a recent study, where DraI RFLP of CYP2El was ana- 
lyzed among 47 lung cancer patients and 56 controls, no 
individuals homozygous for an allelic form termed C 
were found in the cancer group, whereas 6 such individ- 
uals were present in the control group [lo]. This differ- 
ence was considered to be significant. These results 
prompted us to evaluate the frequency of subjects poly- 
morphic for the CYPZEI gene in a Caucasian popula- 
tion and evaluate its possible relationship to incidence 
of lung cancer. 
The CYP2El gene has been shown to be polymorph- 
ically distributed among Japanese, as revealed from 
RFLP analyses using the restriction enzymes RsaI and 
DraI [6], and among Caucasians, as revealed by TaqI 
RFLP [7]. In addition, a polymorphic site in the 5’- 
flanking region constituting a putative HNF-1 binding 
site, has been described among Japanese [8,9]. Because 
2. MATERIALS AND METHODS 
2.1. Isolation of genomic DNA 
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Blood samples were obtained from 151 Swedish ealthy controls, 
55 bronchitis patients and 195 Swedish lung cancer patients from six 
different hospitals in the areas of Stockholm, Gothenburg, Malmo and 
Lund. The material from Gothenburg (40 cases and 16 controls col- 
lected from two hospitals in the West of Sweden) was from a larger 
prospective study. The lung cancer patients all had a history of smok- 
ing and the majority of the histological diagnoses included small cell 
cancer, large cell cancer and squamous cell carcinoma. 27 specimens 
were obtained from subjects with adenocarcinoma. DNA samples 
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from 136 healthy unrelated controls were obtained from sources pre- 
viously described [1 11. Genomic DNA was isolated using a guanidm- 
ium-isothiocyanate method. Blood from the cancer patients and the 
remaining controls was obtained frozen in heparin or EDTA-contain- 
ing tubes. After thawing, the samples were subjected to lysis and 
proteinase digestion before extraction with phenol and chloroform 
[12]. DNA was isolated after ethanol precipitation. 
2.2. RFLP analysis 
Seven fig of genomic DNA was digested overnight with 28 U of the 
restriction endonuclease (Boehringer-Mannheim) in question and then 
subjected to electrophoresis n 1% agarose gel at 30 V for 24 h. Blotting 
was performed with Gene Screen Plus filters (NEN, DuPont) and the 
filter hybridised with a nick translated [‘2P]dCTP (Amersham) labelled 
CYP2El cDNA probe (kindly provided by Dr. F.J. Gonzalez, NCI, 
NIH, Bethesda). 
2.3. Polymorphic analysrs of the 5’-flanking region 
One pg of DNA was subjected to amplification using two designed 
primers; S-CCCGTGAGCCAGTCGAGT-3’ (-1,378 to -1,361) and 
S-ATACAGACCCTCTTCCAC-3’ (-869 to -886), in a reaction cre- 
ating a 510 bp fragment containing both the RsaI and PstI polymor- 
phic sites in the S-flanking area [8]. These polymorphisms have been 
reported to be linked to each other so that each allele type only 
contains one of these restriction sites in the S-flanking region [8]. After 
initial denaturation for 1.5 min at 94°C the PCR reaction was carried 
out for 35 cycles under the following conditions: denaturation at 94°C 
for 1 min; annealing temperature, 52°C for lmin: extention period at 
72’C for 1 min. Five PI of the product was subjected to electrophoresis 
on a 1.8% agarose gel. The remainder was diluted 3-fold with water 
and buffer and subsequently digested with R.ruI for 8812 h. The results 
were analyzed as complete, mcomplete or no fragment cleavage. The 
most common allelic form, c,, has got a RsaI site. When none. or 
incomplete cleavage was obtained, the whole procedure was repeated 
and the fragment digested with PstI as a control for cl. 
2.4. Statistical analysis 
They-test was used and P < 0.05 considered signifi- 
cant. 
3. RESULTS 
3.1. RFLP-analysis of the CYP2El gene among Swedish 
controls and lung cancer cases 
Southern blot analysis of genomic DNA from healthy 
Swedish subjects revealed RFLPs with the restriction 
enzymes DraI, RsaI and TaqI (Fig. 1). The polymorphic 
fragment lengths obtained with DraI were 4.1 and 4.7 
kb. This is different from the length of the DraI poly- 
morphic fragments 5.5 and 4.1 kb, as originally de- 
scribed by Uematsu et al. [6]. In order to exclude inter- 
ethnic differences on this specific point, DraI RFLP was 
performed on DNA obtained from 6 healthy Japanese 
living in Stockholm (cf. Fig. 1). However, under our 
conditions the fragmentation pattern of the Japanese 
DNA was identical with that seen using the Swedish 
samples. These results indicate that the DraI polymor- 
phic site is located in intron 6 (Fig. 1) and not in intron 
3 as originally proposed [lo]. Based on these results and 
because of the presence of two neighbouring DraI cleav- 
age sites in intron 3 [13], we propose that the polymor- 
phic DraI site was erroneously identified in the previous 
report [lo] and therefore use the same nomenclature (C 
and D) for the polymorphic variant alleles. 
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The frequencies of the different C YPZEI alleles iden- 
tified by RFLP were evaluated using DNA obtained 
from healthy controls, bronchitis patients and from pa- 
tients diagnosed for lung cancer (Table I). As compared 
to the previous reports [6, lo], the frequency of the DraI 
C-allele was much lower (0.10) in the Swedish popula- 
tions studied and in total, only two subjects homozy- 
gous for this allele were found. No significant difference 
in the distribution of the C-allele between controls and 
cases could be seen. 
TaqI and RsaI RFLP-analysis revealed the presence 
of two different allelic variants in both cases (Fig. 1, 
Tables I and II). The frequency of the rare allele. de- 
tected with RsaI, was also much lower among the 
Swedes as compared to Japanese. No difference be- 
tween controls and cases was seen for the TaqI poly- 
morphism. 
From Table II it is apparent that the TaqI polymor- 
phism was unrelated to the polymorphisms detected 
with either DraI or RsaI, whereas the 92% of the DraI 
D alleles were of the RsaI H-type. Because of this we did 
not consider it of importance to investigate the distribu- 
tion of the RsaI polymorphism among lung cancer 
cases. 
3.2. Analysis of the 5’--anking region 
Previous data have revealed the existence of a poly- 
morphism in the S-flanking region of CYP2EI at a 
location of -1,017 bp in a putative binding region for 
the transcription factor HNF-1 [8,9]. Preliminary data 
indicating the importance of this polymorphism for 
transcriptional efficiency have been given [9]. Analysis 
of our DNA samples for this polymorphism revealed 
that the frequency of the rare allele (I+) was lower (0.05) 
among healthy Swedes as compared to Japanese. Inter- 
estingly, there was a significant difference (P < 0.05) 
between the two groups studied and among the lung 
cancer patients the corresponding allele frequency was 
only 0.02 (Table I). All haplotypes carrying the c2 allele 
were of the DraI C-type. 
4. DISCUSSION 
The data here presented show that pronounced inter- 
ethnic differences are evident for the genetic polymor- 
phism of CYP2EI. Thus, the rare alleles are much less 
prominent among Swedes, as compared to previous re- 
sults obtained from Japanese subjects [6,9,10]. This is 
true for the polymorphic sites analyzed in the 5’-flank- 
ing region at - 1 ,017 bp [ 131 and the polymorphic sites 
in introns 5 and 6, detected with the restriction enzymes 
RsaI and DraI, respectively. Regarding the polymor- 
phic site in intron 7. as seen with TaqI, it is, however, 
evident that the frequency of the rare allele among 
Swedes is the same as previously seen among Americans 
[7]. These findings further emphasize the importance of 
taking interethnic differences into consideration when 
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Fig. 1. RFLP-analysis of the CYPZEI gene using the restriction en- 
zymes DruI, TaqI and &II. (A) RFLPs obtained using Caucasian 
samples. (B) DraI RFLP obtained using leucocytes from two Japanese 
subjects (lanes 1 and 2) as compared to a Swedish individual (lane 3). 
(C) Schematic drawing of the CYP2El gene illustrating the restriction 
sites. The shadowed area indicates the polymorphic fragments ob- 
tained. A full-length cDNA probe was used in the Southern blot 
experiments. 
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Fig. 2. PCR and RFLP analysis of polymorphism in the 5’-flankmg 
region of the CYPZEl gene. A 510 bp fragment (-1,377 to -868) was 
amplified by PCR and subjected to cleavage using the restrictron 
enzymes Z&I or/and PstI. The figures show the results obtamed wtth 
DNA from subjects homozygous for the c, allele (lane 1). heterozy- 
gous (c,/c~. lane 2) and homozygous for c2 (lane 3). 
discussing specific allelic forms as genetic markers for 
cancer or disease. Previous results from our laboratory 
have revealed important interethnic differences in the 
structure of the CYP2D locus [14-161 with implications 
for the frequency of poor metabolizers of debrisoquine 
among Chinese as compared to Caucasians. 
In contrast to previous results obtained by genetic 
analysis of Japanese subjects, we could not identify any 
significant difference in the distribution of the DraI C- 
allele between controls and lung cancer patients (Table 
I). The same was true for polymorphic distribution of 
the allelic forms identified with RFLP and the restric- 
tion enzyme TuqI. In general, the frequencies of the rare 
CYPZEZ alleles detected by these methods among the 
Swedes would be too low in order to allow to utilize 
them as any potentially valuable markers for lung can- 
cer. Thus, there is a need for further research to find 
other mutations among the Caucasian CYP2El gene 
that could fulfil such a requirement. 
About 50% of the DraI C-alleles also exhibited the 
- 1,017 C + T mutation in the 5’-flanking region. Inter- 
estingly, there was no homogenous distribution of this 
mutation between the controls and the samples from 
lung cancer patients (Table I). Thus, the frequency of 
this mutation among lung cancers was only 40% com- 
pared to its presence in controls. This mutation has been 
assumed to have a functional role [9]. The allelic form 
c2 does less effectively bind nuclear factors to the region 
of the mutation. A similar mutation has been observed 
in the CYP2D6 gene among Chinese of the XbuI 44 kb 
haplotype and the distribution of this mutation very 
well correlates to a diminished capability for debri- 
soquine metabolism among the individuals (Johansson, 
Table I 
Genetic polymorphism of the CYPZEI gene in Swedish controls, 
healthy persons (A) and bronchitis patients (B), and lung cancer pa- 
tients as revealed by RFLP 
(A) DraI RFLP 
Controls Lung cancer 
patients 
A (n=152) B (n=54) (n = 193) 
n (%) n (%) n (%) 
Genotype 
DD 123 81 43 80 160 83 
CD 28 18 10 18 33 17 
cc 1 <l 1 2 0 0 
Allele frequencies 
D 0.90 0.89 0.91 
C 0.10 0.11 0.09 
(B) TuqI RFLP 
Controls Lung cancer 
patients 
A (n=145) B (n=52) (n = 182) 
n (%) n (%) n (%) 
Genotype 
AzA: 116 80 44 85 148 81 
A,Az 28 19 8 15 34 19 
A,A, 1 <1 0 0 0 0 
Allele frequencies 
A, 0.90 0.92 0.91 
A, 0.10 0.08 0.09 
(C) 5’-flanking region 
Controls Lung cancer 
patients 
A (n=148) B (n=54) (n = 184) 
n (%J n (%) n (%) 
Genotype 
CICI 133 90 49 91 176 96 
Cl% 14 9 5 9 8 4 
C& 1 <I 0 0 0 0 
Allele frequencies 
Cl 0.95 0.95 0.98 
C2 0.05 0.05 0.02* 
*The frequency of the cz allele was significantly (P < 0.05) lower 
among the lung cancer cases as compared to the control groups. 
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NOTE ADDED IN PROOF 
Sequence analysis has now revealed that the polymorphic Dt-al site in intron 6 is caused by a 7,766 A -+ T mutation 
(Hu, Y., unpublished results). 
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